Jyong Biotech Ltd. (Nasdaq: MENS) (the 'Company' or 'Jyong Biotech'), a science-driven biotechnology company dedicated to the ...

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG ("Araris") today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) ...

Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...

4P004 is a GLP-1 analog specifically engineered for intra-articular administration in the knee. It is designed to leverage the pleiotropic properties of GLP-1, including analgesic, anti-inflammatory, ...

After launching in 2025 as a refuge for shipwrecked assets from Galapagos, Onco3R Therapeutics is rebranding as Coultreon ...

Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first ...

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

U.S. academic medical centers risk losing leadership in drug discovery and development as global competition—especially from ...

HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immuno-oncology and immune-related diseases, today announced it has selected ...

Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from ...

Lilly will buy Ajax, whose lead medicine is a once-daily pill in the early stages of study for a rare type of blood cancer.

North Carolina’s milestone of exceeding $230 million in biomanufacturing workforce training investments marks an ...